HEADER HYDROLASE/HYDROLASE INHIBITOR 07-FEB-13 4J55 TITLE CRYSTAL STRUCTURE OF MULTIDRUG RESISTANT HIV-1 PROTEASE CLINICAL TITLE 2 ISOLATE PR20 WITH THE POTENT ANTIVIRAL INHIBITOR GRL-02031 COMPND MOL_ID: 1; COMPND 2 MOLECULE: PROTEASE; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: UNP RESIDUES 501-599; COMPND 5 EC: 3.4.23.16; COMPND 6 ENGINEERED: YES; COMPND 7 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HUMAN IMMUNODEFICIENCY VIRUS 1; SOURCE 3 ORGANISM_COMMON: HIV-1; SOURCE 4 ORGANISM_TAXID: 11676; SOURCE 5 GENE: POL; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: BL21(DE3); SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 10 EXPRESSION_SYSTEM_PLASMID: PET11A KEYWDS MULTIDRUG RESISTANT HIV-1 PROTEASE CLINICAL ISOLATE PR20, CLINICAL KEYWDS 2 INHIBITOR AMPRENAVIR, POTENT ANTIVIRAL INHIBITOR GRL-0519A, POTENT KEYWDS 3 ANTIVIRAL INHIBITOR GRL-02031, HYDROLASE-HYDROLASE INHIBITOR COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR Y.-F.WANG,J.AGNISWAMY,I.T.WEBER REVDAT 3 20-SEP-23 4J55 1 REMARK SEQADV REVDAT 2 05-JUN-13 4J55 1 JRNL REVDAT 1 15-MAY-13 4J55 0 JRNL AUTH J.AGNISWAMY,C.H.SHEN,Y.F.WANG,A.K.GHOSH,K.V.RAO,C.X.XU, JRNL AUTH 2 J.M.SAYER,J.M.LOUIS,I.T.WEBER JRNL TITL EXTREME MULTIDRUG RESISTANT HIV-1 PROTEASE WITH 20 MUTATIONS JRNL TITL 2 IS RESISTANT TO NOVEL PROTEASE INHIBITORS WITH JRNL TITL 3 P1'-PYRROLIDINONE OR P2-TRIS-TETRAHYDROFURAN. JRNL REF J.MED.CHEM. V. 56 4017 2013 JRNL REFN ISSN 0022-2623 JRNL PMID 23590295 JRNL DOI 10.1021/JM400231V REMARK 2 REMARK 2 RESOLUTION. 1.31 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : SHELXL-97 REMARK 3 AUTHORS : G.M.SHELDRICK REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.31 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 10.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 90.7 REMARK 3 CROSS-VALIDATION METHOD : FREE R REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (NO CUTOFF). REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : 0.171 REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : 0.168 REMARK 3 FREE R VALUE (NO CUTOFF) : 0.229 REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : 1976 REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : 39412 REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL FOR DATA WITH F>4SIG(F). REMARK 3 R VALUE (WORKING + TEST SET, F>4SIG(F)) : 0.159 REMARK 3 R VALUE (WORKING SET, F>4SIG(F)) : 0.156 REMARK 3 FREE R VALUE (F>4SIG(F)) : 0.217 REMARK 3 FREE R VALUE TEST SET SIZE (%, F>4SIG(F)) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT (F>4SIG(F)) : 1687 REMARK 3 TOTAL NUMBER OF REFLECTIONS (F>4SIG(F)) : 33801 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 1518 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 49 REMARK 3 SOLVENT ATOMS : 116 REMARK 3 REMARK 3 MODEL REFINEMENT. REMARK 3 OCCUPANCY SUM OF NON-HYDROGEN ATOMS : 1655.9 REMARK 3 OCCUPANCY SUM OF HYDROGEN ATOMS : 0.00 REMARK 3 NUMBER OF DISCRETELY DISORDERED RESIDUES : 19 REMARK 3 NUMBER OF LEAST-SQUARES PARAMETERS : 16566 REMARK 3 NUMBER OF RESTRAINTS : 22195 REMARK 3 REMARK 3 RMS DEVIATIONS FROM RESTRAINT TARGET VALUES. REMARK 3 BOND LENGTHS (A) : 0.010 REMARK 3 ANGLE DISTANCES (A) : 0.030 REMARK 3 SIMILAR DISTANCES (NO TARGET VALUES) (A) : 0.000 REMARK 3 DISTANCES FROM RESTRAINT PLANES (A) : 0.030 REMARK 3 ZERO CHIRAL VOLUMES (A**3) : 0.069 REMARK 3 NON-ZERO CHIRAL VOLUMES (A**3) : 0.063 REMARK 3 ANTI-BUMPING DISTANCE RESTRAINTS (A) : 0.014 REMARK 3 RIGID-BOND ADP COMPONENTS (A**2) : 0.004 REMARK 3 SIMILAR ADP COMPONENTS (A**2) : 0.056 REMARK 3 APPROXIMATELY ISOTROPIC ADPS (A**2) : 0.000 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED: MOEWS & KRETSINGER, J.MOL.BIOL.91(1973)201-228 REMARK 3 REMARK 3 STEREOCHEMISTRY TARGET VALUES : ENGH AND HUBER REMARK 3 SPECIAL CASE: NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: ANISOTROPIC REFINEMENT REDUCED FREE R REMARK 3 (NO CUTOFF) REMARK 4 REMARK 4 4J55 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 13-FEB-13. REMARK 100 THE DEPOSITION ID IS D_1000077608. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 08-OCT-08 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 4.8 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : APS REMARK 200 BEAMLINE : 22-ID REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.8 REMARK 200 MONOCHROMATOR : ROSENBAUM-ROCK DOUBLE-CRYSTAL REMARK 200 SI(111) REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : MARMOSAIC 300 MM CCD REMARK 200 INTENSITY-INTEGRATION SOFTWARE : HKL-2000 REMARK 200 DATA SCALING SOFTWARE : HKL-2000 REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 39582 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.310 REMARK 200 RESOLUTION RANGE LOW (A) : 50.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 90.8 REMARK 200 DATA REDUNDANCY : 5.500 REMARK 200 R MERGE (I) : 0.07600 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 16.2000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.31 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.36 REMARK 200 COMPLETENESS FOR SHELL (%) : 90.8 REMARK 200 DATA REDUNDANCY IN SHELL : 2.30 REMARK 200 R MERGE FOR SHELL (I) : 0.26300 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 3.000 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASES REMARK 200 STARTING MODEL: PDB ENTRY 2HS2 REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 40.17 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.06 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 1.2 M LITHIUM CHLORIDE, 0.1 M SODIUM REMARK 280 ACETATE, PH 4.8, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 14.32100 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 46.85650 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 32.98350 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 46.85650 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 14.32100 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 32.98350 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 3970 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 9830 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -25.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 O HOH A 336 O HOH A 337 1.67 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 ARG A 41 NE - CZ - NH1 ANGL. DEV. = -5.0 DEGREES REMARK 500 ARG A 41 NE - CZ - NH2 ANGL. DEV. = 4.6 DEGREES REMARK 500 ARG A 57 NE - CZ - NH1 ANGL. DEV. = -3.7 DEGREES REMARK 500 ARG A 87 NE - CZ - NH1 ANGL. DEV. = 3.8 DEGREES REMARK 500 ARG A 87 NE - CZ - NH2 ANGL. DEV. = -3.9 DEGREES REMARK 500 LEU B 54 CA - CB - CG ANGL. DEV. = 18.6 DEGREES REMARK 500 ARG B 57 NE - CZ - NH1 ANGL. DEV. = -3.2 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 TRP B 42 -153.42 -148.87 REMARK 500 REMARK 500 REMARK: NULL REMARK 610 REMARK 610 MISSING HETEROATOM REMARK 610 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 610 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 610 I=INSERTION CODE): REMARK 610 M RES C SSEQI REMARK 610 031 A 202 REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 031 A 201 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 031 A 202 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 3UCB RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF MULTIDRUG RESISTANT HIV-1 PROTEASE CLINICAL REMARK 900 ISOLATE PR20 WITH DARUNAVIR REMARK 900 RELATED ID: 3UFN RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF MULTIDRUG RESISTANT HIV-1 PROTEASE CLINICAL REMARK 900 ISOLATE PR20 WITH SAQUINAVIR REMARK 900 RELATED ID: 3UF3 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF MULTIDRUG RESISTANT HIV-1 PROTEASE CLINICAL REMARK 900 ISOLATE PR20 WITH YTTRIUM(III) CHLORIDE REMARK 900 RELATED ID: 3UHL RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF MULTIDRUG RESISTANT HIV-1 PROTEASE CLINICAL REMARK 900 ISOLATE PR20 WITH THE P2-NC SUBSTRATE ANALOG REMARK 900 RELATED ID: 4J54 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF MULTIDRUG RESISTANT HIV-1 PROTEASE CLINICAL REMARK 900 ISOLATE PR20 WITH THE POTENT ANTIVIRAL INHIBITOR GRL-0519A REMARK 900 RELATED ID: 3H5B RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF WILD-TYPE HIV-1 PROTEASE WITH THE POTENT REMARK 900 ANTIVIRAL INHIBITOR GRL-02031 REMARK 900 RELATED ID: 4J5J RELATED DB: PDB DBREF 4J55 A 1 99 UNP P03367 POL_HV1BR 501 599 DBREF 4J55 B 1 99 UNP P03367 POL_HV1BR 501 599 SEQADV 4J55 LYS A 7 UNP P03367 GLN 507 ENGINEERED MUTATION SEQADV 4J55 PHE A 10 UNP P03367 LEU 510 ENGINEERED MUTATION SEQADV 4J55 VAL A 13 UNP P03367 ILE 513 ENGINEERED MUTATION SEQADV 4J55 VAL A 15 UNP P03367 ILE 515 ENGINEERED MUTATION SEQADV 4J55 ASN A 30 UNP P03367 ASP 530 ENGINEERED MUTATION SEQADV 4J55 ILE A 32 UNP P03367 VAL 532 ENGINEERED MUTATION SEQADV 4J55 PHE A 33 UNP P03367 LEU 533 ENGINEERED MUTATION SEQADV 4J55 ASP A 35 UNP P03367 GLU 535 ENGINEERED MUTATION SEQADV 4J55 ILE A 36 UNP P03367 MET 536 ENGINEERED MUTATION SEQADV 4J55 ASN A 37 UNP P03367 SER 537 ENGINEERED MUTATION SEQADV 4J55 VAL A 47 UNP P03367 ILE 547 ENGINEERED MUTATION SEQADV 4J55 LEU A 54 UNP P03367 ILE 554 ENGINEERED MUTATION SEQADV 4J55 GLU A 58 UNP P03367 GLN 558 ENGINEERED MUTATION SEQADV 4J55 VAL A 62 UNP P03367 ILE 562 ENGINEERED MUTATION SEQADV 4J55 PRO A 63 UNP P03367 LEU 563 ENGINEERED MUTATION SEQADV 4J55 ALA A 67 UNP P03367 CYS 567 ENGINEERED MUTATION SEQADV 4J55 VAL A 71 UNP P03367 ALA 571 ENGINEERED MUTATION SEQADV 4J55 VAL A 84 UNP P03367 ILE 584 ENGINEERED MUTATION SEQADV 4J55 ASP A 88 UNP P03367 ASN 588 ENGINEERED MUTATION SEQADV 4J55 THR A 89 UNP P03367 LEU 589 ENGINEERED MUTATION SEQADV 4J55 MET A 90 UNP P03367 LEU 590 ENGINEERED MUTATION SEQADV 4J55 ALA A 95 UNP P03367 CYS 595 ENGINEERED MUTATION SEQADV 4J55 LYS B 7 UNP P03367 GLN 507 ENGINEERED MUTATION SEQADV 4J55 PHE B 10 UNP P03367 LEU 510 ENGINEERED MUTATION SEQADV 4J55 VAL B 13 UNP P03367 ILE 513 ENGINEERED MUTATION SEQADV 4J55 VAL B 15 UNP P03367 ILE 515 ENGINEERED MUTATION SEQADV 4J55 ASN B 30 UNP P03367 ASP 530 ENGINEERED MUTATION SEQADV 4J55 ILE B 32 UNP P03367 VAL 532 ENGINEERED MUTATION SEQADV 4J55 PHE B 33 UNP P03367 LEU 533 ENGINEERED MUTATION SEQADV 4J55 ASP B 35 UNP P03367 GLU 535 ENGINEERED MUTATION SEQADV 4J55 ILE B 36 UNP P03367 MET 536 ENGINEERED MUTATION SEQADV 4J55 ASN B 37 UNP P03367 SER 537 ENGINEERED MUTATION SEQADV 4J55 VAL B 47 UNP P03367 ILE 547 ENGINEERED MUTATION SEQADV 4J55 LEU B 54 UNP P03367 ILE 554 ENGINEERED MUTATION SEQADV 4J55 GLU B 58 UNP P03367 GLN 558 ENGINEERED MUTATION SEQADV 4J55 VAL B 62 UNP P03367 ILE 562 ENGINEERED MUTATION SEQADV 4J55 PRO B 63 UNP P03367 LEU 563 ENGINEERED MUTATION SEQADV 4J55 ALA B 67 UNP P03367 CYS 567 ENGINEERED MUTATION SEQADV 4J55 VAL B 71 UNP P03367 ALA 571 ENGINEERED MUTATION SEQADV 4J55 VAL B 84 UNP P03367 ILE 584 ENGINEERED MUTATION SEQADV 4J55 ASP B 88 UNP P03367 ASN 588 ENGINEERED MUTATION SEQADV 4J55 THR B 89 UNP P03367 LEU 589 ENGINEERED MUTATION SEQADV 4J55 MET B 90 UNP P03367 LEU 590 ENGINEERED MUTATION SEQADV 4J55 ALA B 95 UNP P03367 CYS 595 ENGINEERED MUTATION SEQRES 1 A 99 PRO GLN ILE THR LEU TRP LYS ARG PRO PHE VAL THR VAL SEQRES 2 A 99 LYS VAL GLY GLY GLN LEU LYS GLU ALA LEU LEU ASP THR SEQRES 3 A 99 GLY ALA ASP ASN THR ILE PHE GLU ASP ILE ASN LEU PRO SEQRES 4 A 99 GLY ARG TRP LYS PRO LYS MET VAL GLY GLY ILE GLY GLY SEQRES 5 A 99 PHE LEU LYS VAL ARG GLU TYR ASP GLN VAL PRO ILE GLU SEQRES 6 A 99 ILE ALA GLY HIS LYS VAL ILE GLY THR VAL LEU VAL GLY SEQRES 7 A 99 PRO THR PRO VAL ASN VAL ILE GLY ARG ASP THR MET THR SEQRES 8 A 99 GLN ILE GLY ALA THR LEU ASN PHE SEQRES 1 B 99 PRO GLN ILE THR LEU TRP LYS ARG PRO PHE VAL THR VAL SEQRES 2 B 99 LYS VAL GLY GLY GLN LEU LYS GLU ALA LEU LEU ASP THR SEQRES 3 B 99 GLY ALA ASP ASN THR ILE PHE GLU ASP ILE ASN LEU PRO SEQRES 4 B 99 GLY ARG TRP LYS PRO LYS MET VAL GLY GLY ILE GLY GLY SEQRES 5 B 99 PHE LEU LYS VAL ARG GLU TYR ASP GLN VAL PRO ILE GLU SEQRES 6 B 99 ILE ALA GLY HIS LYS VAL ILE GLY THR VAL LEU VAL GLY SEQRES 7 B 99 PRO THR PRO VAL ASN VAL ILE GLY ARG ASP THR MET THR SEQRES 8 B 99 GLN ILE GLY ALA THR LEU ASN PHE HET 031 A 201 42 HET 031 A 202 7 HETNAM 031 (3AS,5R,6AR)-HEXAHYDRO-2H-CYCLOPENTA[B]FURAN-5-YL [(1S, HETNAM 2 031 2R)-1-BENZYL-2-HYDROXY-3-([(4-METHOXYPHENYL) HETNAM 3 031 SULFONYL]{[(2R)-5-OXOPYRROLIDIN-2-YL]METHYL}AMINO) HETNAM 4 031 PROPYL]CARBAMATE FORMUL 3 031 2(C30 H39 N3 O8 S) FORMUL 5 HOH *116(H2 O) HELIX 1 1 GLY A 86 THR A 91 1 6 HELIX 2 2 GLN A 92 GLY A 94 5 3 HELIX 3 3 GLY B 86 ILE B 93 1 8 SHEET 1 A 4 GLN A 2 ILE A 3 0 SHEET 2 A 4 THR B 96 ASN B 98 -1 O LEU B 97 N ILE A 3 SHEET 3 A 4 THR A 96 ASN A 98 -1 N THR A 96 O ASN B 98 SHEET 4 A 4 GLN B 2 ILE B 3 -1 O ILE B 3 N LEU A 97 SHEET 1 B 8 LYS A 43 GLY A 48 0 SHEET 2 B 8 PHE A 53 ILE A 66 -1 O GLU A 58 N LYS A 43 SHEET 3 B 8 HIS A 69 VAL A 77 -1 O VAL A 71 N ILE A 64 SHEET 4 B 8 ILE A 32 PHE A 33 1 N PHE A 33 O LEU A 76 SHEET 5 B 8 VAL A 84 ILE A 85 -1 O VAL A 84 N ILE A 32 SHEET 6 B 8 GLN A 18 LEU A 24 1 N LEU A 23 O ILE A 85 SHEET 7 B 8 PHE A 10 VAL A 15 -1 N VAL A 13 O LYS A 20 SHEET 8 B 8 PHE A 53 ILE A 66 -1 O GLU A 65 N LYS A 14 SHEET 1 C 8 LYS B 43 GLY B 49 0 SHEET 2 C 8 GLY B 52 ILE B 66 -1 O GLU B 58 N LYS B 43 SHEET 3 C 8 HIS B 69 VAL B 77 -1 O VAL B 71 N ILE B 64 SHEET 4 C 8 ILE B 32 PHE B 33 1 N PHE B 33 O LEU B 76 SHEET 5 C 8 VAL B 84 ILE B 85 -1 O VAL B 84 N ILE B 32 SHEET 6 C 8 GLN B 18 LEU B 24 1 N LEU B 23 O ILE B 85 SHEET 7 C 8 PHE B 10 VAL B 15 -1 N VAL B 13 O LYS B 20 SHEET 8 C 8 GLY B 52 ILE B 66 -1 O GLU B 65 N LYS B 14 SITE 1 AC1 21 LEU A 23 ASP A 25 GLY A 27 ALA A 28 SITE 2 AC1 21 ASP A 29 ASN A 30 GLY A 48 GLY A 49 SITE 3 AC1 21 ILE A 50 VAL A 82 HOH A 321 ASP B 25 SITE 4 AC1 21 GLY B 27 ALA B 28 ASN B 30 ILE B 32 SITE 5 AC1 21 GLY B 48 GLY B 49 ILE B 50 VAL B 82 SITE 6 AC1 21 HOH B1001 SITE 1 AC2 6 PRO A 44 LYS A 55 VAL A 56 GLN A 92 SITE 2 AC2 6 ILE A 93 GLY A 94 CRYST1 28.642 65.967 93.713 90.00 90.00 90.00 P 21 21 21 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.034914 0.000000 0.000000 0.00000 SCALE2 0.000000 0.015159 0.000000 0.00000 SCALE3 0.000000 0.000000 0.010671 0.00000